Brief: Immunocore Reports Updated Phase 1 Data Of Brenetafusp (Imc-F106c), An Immtac Bispecific Targeting Prame, In Immune Checkpoint Pre-Treated Cutaneous Melanoma Patients At Asco 2024

Immunocore Holdings

31/05/2024 22:04

Immunocore Holdings PLC  IMCR.O :
    * IMMUNOCORE REPORTS UPDATED PHASE 1 DATA OF BRENETAFUSP
(IMC-F106C), AN IMMTAC BISPECIFIC TARGETING PRAME, IN IMMUNE
CHECKPOINT PRE-TREATED CUTANEOUS MELANOMA PATIENTS AT ASCO 2024
    * IMMUNOCORE  - MONOTHERAPY BRENETAFUSP IN LATE-LINE
CUTANEOUS
MELANOMA DEMONSTRATED PROMISING DISEASE CONTROL (PARTIAL
RESPONSE AND STABLE DISEASE)
    * IMMUNOCORE  -  MONOTHERAPY BRENETAFUSP IN LATE-LINE
CUTANEOUS
MELANOMA DEMONSTRATED PROMISING PROGRESSION FREE SURVIVAL AND
CTDNA MOLECULAR RESPONSE
    * IMMUNOCORE  - BRENETAFUSP IS WELL TOLERATED AS MONOTHERAPY
AND
IN COMBINATION WITH ANTI-PD1

Source text for Eikon:  ID:nGNX25Vl5k 
Further company coverage:  IMCR.O